Enveric Biosciences (ENVB) Retained Earnings (2010 - 2026)
Enveric Biosciences (ENVB) posted Retained Earnings of $122.1 million for Q1 2026, up 206.32% sequentially from -$114.8 million in Q4 2025, and up 20519.42% YoY from N/an in Q1 2025.
Enveric Biosciences (ENVB) Retained Earnings (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Retained Earnings for 17 years, with the latest figure at $122.1 million in Q1 2026.
- Quarterly Retained Earnings rose 20519.42% year-over-year to $122.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122.1 million (up 20519.42% YoY) and the FY2025 annual result came in at -$114.8 million, down 19217.61% from the prior year.
- Retained Earnings improved to $122.1 million in Q1 2026 per ENVB's latest filing, from -$114.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at $122.1 million in Q1 2026 and troughed at -$114.8 million in Q4 2025.
- A 5-year average of $18.8 million and a median of -$551843.0 in 2024 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 21910.22% in 2025, down 19217.61% in 2025.
- Over 5 years, Retained Earnings stood at -$79.2 million in 2022, then jumped by 99.28% to -$569749.0 in 2023, then slipped by 4.35% to -$594517.0 in 2024, then plunged by 19217.61% to -$114.8 million in 2025, then soared by 206.32% to $122.1 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $122.1 million, -$114.8 million, and $116.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 128.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 122.11 Mn |
| Dec 31, 2025 | -114.85 Mn |
| Sep 30, 2025 | 116.68 Mn |
| Jun 30, 2025 | -573,531.00 |
| Mar 31, 2025 | -598,004.00 |
| Dec 31, 2024 | -594,517.00 |
| Sep 30, 2024 | -534,998.00 |
| Jun 30, 2024 | -566,495.00 |
| Mar 31, 2024 | -551,843.00 |
| Dec 31, 2023 | -569,749.00 |
| Sep 30, 2023 | 96.01 Mn |
| Jun 30, 2023 | -90.24 Mn |
| Mar 31, 2023 | -534,766.00 |
| Dec 31, 2022 | -79.21 Mn |
| Sep 30, 2022 | 93.99 Mn |
| Jun 30, 2022 | 90.23 Mn |
| Mar 31, 2022 | 89.12 Mn |
| Dec 31, 2021 | -60.74 Mn |
| Sep 30, 2021 | -18.63 Mn |
| Jun 30, 2021 | 34.70 Mn |